Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles

Molecular Pharmaceutics

Volumn 12, Issue 2, 2015, Pages 420-431

  Serrano, Dolores R ^a   Lalatsa, Aikaterini ^b   Dea Ayuela, M Auxiliadora ^c   Bilbao Ramos, Pablo E ^a   Garrett, Natalie L ^d   Moger, Julian ^d   Guarro, Josep ^e   Capilla, Javier ^e   Ballesteros, M Paloma ^a   Schätzlein, Andreas G ^f   Bolás, Francisco ^a   Torrado, Juan J ^a   Uchegbu, Ijeoma F ^f,g  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^d UNIVERSITY OF EXETER   (United Kingdom)

^e UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^f UNIVERSITY OF LONDON   (United Kingdom)

^g NANOMERICS LTD   (United Kingdom)

Author keywords

amphotericin B; N palmitoyl, N methyl N, N dimethyl N, N, N trimethyl 6 O glycol chitosan; nanomedicine; nanoparticles; oral delivery

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; N PALMITOYL N METHYL N,N DIMETHYL N,N,N TRIMETHYL 6 O GLYCOL CHITOSAN; NANOPARTICLE; POLYMER; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; BEAGLE; CANDIDIASIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; MALE; MOUSE; NANOENCAPSULATION; NANOMEDICINE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TARGET ORGAN; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG STABILITY; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ANTIPROTOZOAL AGENTS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; MALE; MICE; MICE, INBRED BALB C; NANOMEDICINE; NANOPARTICLES;

EID: 84961289924     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500527x     Document Type: Article

References (31)

1. Kirkpatrick, P. Pressures in the pipeline Nat. Rev. Drug Discovery 2003, 2, 337
2. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 2004, 3 (8) 711-5
3. Strickley, R. G. Solubilizing excipients in oral and injectable formulations Pharm. Res. 2004, 21 (2) 201-30
4. Jibodh, R. A.; Lagas, J. S.; Nuijen, B.; Beijnen, J. H.; Schellens, J. H. M. Taxanes: Old drugs, new oral formulations Eur. J. Pharmacol. 2013, 717 (1-3) 40-6
5. Chaturvedi, K.; Ganguly, K.; Nadagouda, M. N.; Aminabhavi, T. M. Polymeric hydrogels for oral insulin delivery J. Controlled Release 2013, 165 (2) 129-38
6. Meyer, R. D. Current role of therapy with amphotericin B Clin. Infect. Dis. 1992, 14 (Suppl. 1) S154-60
7. Torrado, J. J.; Espada, R.; Ballesteros, M. P.; Torrado-Santiago, S. Amphotericin B formulations and drug targeting J. Pharm. Sci. 2008, 97 (7) 2405-25
8. Bes, D. F.; Sberna, N.; Rosanova, M. T. [Advantages and drawbacks of amphotericin formulations in children: literature review] Arch. Argent. Pediatr. 2012, 110 (1) 46-51
9. Torrado, J.; Serrano, D.; Uchegbu, I. The oral delivery of amphotericin B Ther. Delivery 2013, 4 (1) 9-12
10. Ching, M. S.; Raymony, K.; Bury, R. W.; Mashford, M. L.; Morgan, D. J. Absorption of orally adminsitered amphotericin B lozenges Br. J. Clin. Pharmacol. 1983, 16, 106-8
11. Qu, X.; Khutoryanskiy, V. V.; Stewart, A.; Rahman, S.; Papahadjopoulos-Sternberg, B.; Dufes, C.; McCarthy, D.; Wilson, C. G.; Lyons, R.; Carter, K. C.; Schatzlein, A.; Uchegbu, I. F. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude Biomacromolecules 2006, 7 (12) 3452-9
12. Siew, A.; Le, H.; Thiovolet, M.; Gellert, P.; Schatzlein, A.; Uchegbu, I. Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharmaceutics 2012, 9 (1) 14-28
13. Garrett, N. L.; Lalatsa, A.; Uchegbu, I.; Schatzlein, A.; Moger, J. Exploring uptake mechanisms of oral nanomedicines using multimodal nonlinear optical microscopy J. Biophotonics 2012, 5 (5-6) 458-68
14. Lalatsa, A.; Lee, V.; Malkinson, J. P.; Zloh, M.; Schatzlein, A. G.; Uchegbu, I. F. A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain Mol. Pharmaceutics 2012, 9 (6) 1665-80
15. Uchegbu, I. F.; Sadiq, L.; Arastoo, M.; Gray, A. I.; Wang, W.; Waigh, R. D.; Schatzlein, A. G. Quaternary ammonium palmitoyl glycol chitosan - a new polysoap for drug delivery Int. J. Pharm. 2001, 224 (1-2) 185-99
16. Lalatsa, A.; Garrett, N. L.; Ferrarelli, T.; Moger, J.; Schatzlein, A. G.; Uchegbu, I. F. Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharmaceutics 2012, 9 (6) 1764-74
17. Espada, R.; Josa, J. M.; Valdespina, S.; Dea, M. A.; Ballesteros, M. P.; Alunda, J. M.; Torrado, J. J. HPLC assay for determination of amphotericin B in biological samples Biomed. Chromatogr. 2008, 22 (4) 402-7
18. Dea-Ayuela, M. A.; Castillo, E.; Gonzalez-Alvarez, M.; Vega, C.; Rolon, M.; Bolas-Fernandez, F.; Borras, J.; Gonzalez-Rosende, M. E. In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide Bioorg. Med. Chem. 2009, 17 (21) 7449-56
19. Hill, J. O.; North, R. J.; Collins, F. M. Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis Infect. Immun. 1983, 39 (3) 1087-94
20. Titus, R. G.; Marchand, M.; Boon, T.; Louis, J. A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice Parasite Immunol. 1985, 7 (5) 545-55
21. Manandhar, K. D.; Yadav, T. P.; Prajapati, V. K.; Kumar, S.; Rai, M.; Dube, A.; Srivastava, O. N.; Sundar, S. Antileishmanial activity of nano-amphotericin B deoxycholate J. Antimicrob. Chemother. 2008, 62 (2) 376-80
22. Bellmann, R. Clinical pharmacokinetics of systemically administered antimycotics Curr. Clin. Pharmacol. 2007, 2, 37-58
23. Fielding, R. M.; Singer, A. W.; Wang, L. H.; Babbar, S.; Guo, L. S. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs Antimicrob. Agents Chemother. 1992, 36, 299-307
24. Nishimoto, G.; Tsunoda, Y.; Nagata, M.; Yamaguchi, Y.; Yoshioka, T.; Ito, K. Acute renal failure associated with Candida albicans infection Pediatr. Nephrol. 1995, 9 (4) 480-2
25. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 2005, 22 (1) 11-23
26. Sivak, O.; Gershkovich, P.; Lin, M.; Wasan, E. K.; Zhao, J.; Owen, D.; Clement, J. G.; Wasan, K. M. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model Lipids Health Dis. 2011, 10, 135
27. Gershkovich, P.; Sivak, O.; Wasan, E. K.; Magil, A. B.; Owen, D.; Clement, J. G.; Wasan, K. M. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009) J. Antimicrob. Chemother. 2010, 65 (12) 2610-3
28. Risovic, V.; Boyd, M.; Choo, E.; Wasan, K. M. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats Antimicrob. Agents Chemother. 2003, 47 (10) 3339-42
29. Sagawa, K.; Li, F.; Liese, R.; Sutton, S. Fed and Fasted Gastric pH and Gastric Residence Time in Conscious Beagle Dogs J. Pharm. Sci. 2009, 98 (7) 2494-500
30. McConnell, E. L.; Basit, A. W.; Murdan, S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments J. Pharm. Pharmacol. 2008, 60 (1) 63-70
31. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans Pharm. Res. 1993, 10 (7) 1093-5